Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
35.28
-0.69 (-1.92%)
At close: Mar 3, 2026, 4:00 PM EST
35.26
-0.02 (-0.06%)
After-hours: Mar 3, 2026, 6:06 PM EST

Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 105.2, with a low estimate of 60 and a high estimate of 150. The average target predicts an increase of 198.19% from the current stock price of 35.28.

Analyst Consensus: Buy
Target Low Average Median High
Price $60 $105.2 $100 $150
Change +70.07% +198.19% +183.45% +325.17%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '25Nov '25Dec '25Jan '26Feb '26Mar '26
Strong Buy 333333
Buy 111111
Hold 012222
Sell 000000
Strong Sell 000000
Total 456666

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$67$60
Strong Buy Maintains $67$60 +70.07% Feb 25, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$105$67
Strong Buy Maintains $105$67 +89.91% Feb 20, 2026
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$99$100
Strong Buy Maintains $99$100 +183.45% Jan 23, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$90$105
Strong Buy Maintains $90$105 +197.62% Jan 23, 2026
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$140$99
Strong Buy Maintains $140$99 +180.61% Jan 2, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
994.62M
from 761.41M
Increased by 30.63%
Revenue Next Year
1.31B
from 994.62M
Increased by 31.61%
EPS This Year
0.62
from 0.82
Decreased by -24.54%
EPS Next Year
3.14
from 0.62
Increased by 406.87%
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
365.98M401.86M482.38M675.04M761.41M994.62M1.31B
Revenue Growth
3.42%9.80%20.04%39.94%12.79%30.63%31.61%
EPS
0.890.870.941.230.820.623.14
EPS Growth
4.71%-2.25%8.05%30.85%-33.33%-24.54%406.87%
Forward PE
-----57.0111.25
No. Analysts -----86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027202820292030
High 1.1B 1.8B
Avg 994.6M 1.3B
Low 826.1M 934.1M

Revenue Growth

Revenue Growth 20262027202820292030
High
49.9%
77.8%
Avg
30.6%
31.6%
Low
8.5%
-6.1%

EPS Forecast

EPS 20262027202820292030
High 1.50 4.20
Avg 0.62 3.14
Low -0.91 2.46

EPS Growth

EPS Growth 20262027202820292030
High
83.1%
578.7%
Avg
-24.5%
406.9%
Low -
297.5%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.